## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## DIAGNOSTICS ASSESSMENT PROGRAMME

**Equality impact assessment – Guidance development** 

Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)

## Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

During scoping it was identified that bacterial sepsis may be more difficult to identify in pregnant women, young children, older people and people with a mental health problem.

The External Assessment Group did not identify any evidence of differential outcomes in these subgroups.

2. Have any other potential equality issues been raised in the second assessment subgroup meeting (if held) and in the evidence assessment and analysis report, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during the assessment.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No other potential equality issues were identified by the Committee.

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?				
No					
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?				
No					
6.	Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?				
No					
7.	Have the Committee's considerations of equality issues been described in the diagnostics consultation document, and, if so, where?				
No potential equality issues were identified.					

Approved by Associate Director (name): ... Carla Deakin.....

**Date: 23 July 2015** 

## **Diagnostics guidance document**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations did not change substantially after consultation.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations did not change substantially after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations did not change substantially after consultation.

5. Have the Committee's considerations of equality issues been described in the diagnostics guidance document, and, if so, where?

No potential equality issues were identified.

Approved b	by Centre or I	Programme I	Director (	(name):	 

Date: [xx/xx/year]